PPT-AFLIBERCEPT DB08885 C 4318
Author : faustina-dinatale | Published Date : 2018-02-17
H 6788 N 1164 O 1304 S 32 115 kDa with glycosylation Eylea Regeneron Pharmaceuticals Zaltrap Regeneron Pharmaceuticals CATEGORY Antineoplastic Agents
Presentation Embed Code
Download Presentation
Download Presentation The PPT/PDF document "AFLIBERCEPT DB08885 C 4318" is the property of its rightful owner. Permission is granted to download and print the materials on this website for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
AFLIBERCEPT DB08885 C 4318: Transcript
H 6788 N 1164 O 1304 S 32 115 kDa with glycosylation Eylea Regeneron Pharmaceuticals Zaltrap Regeneron Pharmaceuticals CATEGORY Antineoplastic Agents . Current understanding and . approaches to treatment. Prescribing information can be found on the last two slides. About this slide deck. This slide deck is provided as a service to medicine by Bayer and is intended for educational use with healthcare professionals . Charles C. Wykoff, MD, PhD, FACS. Physician, Retina . Consultants of Houston. Blanton Eye Institute & . Houston Methodist Hospital. Houston, USA. Faculty. Scope of the Problem. 1st WHO Global Report: 1/12 . Comparative Effectiveness of Aflibercept, Bevacizumab, and Ranibizumab for DME. Supported through a cooperative agreement from the . National Eye Institute; National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health, Department of Health and Human Services EY14231, EY14229, EY018817 . age-related macular degeneration. Salman Sarwar, Elizabeth Clearfield, Mohamed Soliman, Mohammed Sadiq, Andrew Baldwin, Mostafa Hanout, Aniruddha Agarwal, Yasir Sepah, Diana Do, Quan Nguyen. Issue 2, 2016. 1. Disclosures. Supported by the National Eye Institute and the National Institute of Diabetes and Digestive and Kidney Diseases under award numbers UG1EY014231 and UG1EY023207. . Regeneron provided aflibercept for the study and funds to the DRCR Retina Network to defray the study’s clinical site costs..
Download Document
Here is the link to download the presentation.
"AFLIBERCEPT DB08885 C 4318"The content belongs to its owner. You may download and print it for personal use, without modification, and keep all copyright notices. By downloading, you agree to these terms.
Related Documents
